Edgar Filing: ENDOCYTE INC - Form 4

ENDOCYTE INC

Form 4											
February 10, FORM	4 UNITED	STATES		ITIES A hington,			NGE (COMMISSION		PPROVAL 3235-0287	
Check this if no long subject to Section 10 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	er STATEN 5. Filed put ¹⁵ Section 17(rsuant to S (a) of the I	Section 16	SECUR (a) of the lity Hold	ITIES e Securiti ling Com	ies Ex ipany	chang Act o	NERSHIP OF ge Act of 1934, f 1935 or Sectio 40	Expires: Estimated a burden hou response	rs per	
(Print or Type R	esponses)										
Brinkley Michael A. Symbol				r Name and Ticker or Trading CYTE INC [ECYT]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) 3000 KENT A1-100	(First) (AVENUE, SUI	Middle) TE	3. Date of (Month/Da 02/06/20	y/Year)	ansaction			Director X Officer (give below)	10%	9 Owner er (specify	
				mendment, Date Original Ionth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
WEST LAF	AYETTE, IN 47	906						Person	viore than One Re	eporting	
(City)	(State)	(Zip)	Table	I - Non-D	erivative S	Securi	ties Ac	quired, Disposed o	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year) Executio any	med n Date, if Day/Year)	3. Transactio Code (Instr. 8)	4. Securi onAcquirec Disposec (Instr. 3,	l (A) o l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	02/06/2014			Code V A	Amount 6,250 (1)	(D) A	Price \$ 0	(Instr. 3 and 4) 6,250	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: ENDOCYTE INC - Form 4

De Se	Title of erivative courity nstr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerce Expiration D (Month/Day/	ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 E S (1
					Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
0 (r	ock ption ight to	\$ 11.11	02/06/2014		A	37,500	(2)	02/06/2024	Common Stock	37,500	
Reporting Owners											
Reporting Owner Name / Address Director 10% Owner Officer Other											
B	Brinkley Michael A.										

Brinkley Michael A. 3000 KENT AVENUE, SUITE A1-100 WEST LAFAYETTE, IN 47906

Signatures

/s/ Beth A. Taylor, Attorney-in-fact for Michael A. Brinkley (power of attorney previously filed)					
<u>**</u> Signature of Reporting Person	Date				

VP OF QUALITY

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents restricted stock units that will vest and be paid 1/4 annually over a period of 4 years beginning on February 6, 2015, in the form of one share of common stock for each restricted stock unit.
- (2) Shares subject to the option vest 1/4 annually over a period of 4 years beginning on February 6, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.